Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration

Ophthalmology and Therapy

Volumn 6, Issue 1, 2017, Pages 141-146

  Kapoor, Kapil G ^a   Todi, Niket ^a   Wagner, Alan L ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Central serous retinopathy; Mineralocorticoid antagonists; Neovascular AMD; Subretinal fluid; Wet AMD

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; EPLERENONE; MINERALOCORTICOID;

ADULT; AGED; ARTICLE; CASE REPORT; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MACULAR EDEMA; MALE; MIDDLE AGED; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SUBRETINAL FLUID; WET MACULAR DEGENERATION;

EID: 85044154816     PISSN: 21938245     EISSN: 21936528     Source Type: Journal    
DOI: 10.1007/s40123-016-0075-1     Document Type: Article

References (11)

1. Zhao M, Celerier I, Bousquet E, Jeanny JC, Jonet L, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122(7):2672–9.
2. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy; a pilot study. Retina. 2013;33(10):2096–102.
3. Herold TR, Prause K, Wolf A, Mayer WJ, Ulbig MW. Spironolactone in the treatment of central serous chorioretinopathy—case series. Graefes Arch Clin Exp Ophthalmol. 2014;252(12):1985–91.
4. Hasegawa T, Okamoto M, Masuda N, Ueda T, Ogata N. Relationship between foveal microstructures and visual outcomes in eyes with resolved central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(3):343–50.
5. Shing JY, Woo SJ, Ahn J, Park KH. Anti-VEGF refractory exudative age-related macular degeneration; differential response according to features on optical coherence tomography. Korean J Ophthalmol. 2013;27(6):425–32.
6. Kloos P, Niederberger H, Valmaggia C. Photodynamic therapy in “secondary sick RPE syndrome” after repeated intravitreal injections of VEGF inhibitors in patients with wet age-related macular degeneration. Klin Monbl Augenheilkd. 2011;228(4):340–4.
7. Broadhead GK, Hong T, Chang AA. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92(8):713–23.
8. Xu L, Mrejen S, Jung JJ, et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina. 2015;35:176–86.
9. Nair U, Ganekal S, Soman M, Nair K. Correlation of spectral domain optical coherence tomography findings in acute central serous chorioretinopathy with visual acuity. Clin Ophthalmol. 2013;6:1949–54.
10. Gallego-Pinazo R, Dolz-Marco R, Gomez-Ulla F, Mrejen S, Freund KB. Pachychoroid disease of the macula. Med Hypothesis Discov Innov Ophthalmol. 2014;3(4):111–5.
11. Matzumoto H, Kishi S, Otani T, Sato T. Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol. 2008;145(1):162–8.